Blog

The latest thoughts from Medicines Law & Policy partners.

Will Europe block the Pandemic Agreement because of one word?

This commentary originally appeared in the Brussels Times, and is available here. The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...

We need a Global Vaccines Taskforce, not just a British or European one

The European Commission has been heavily criticised for its performance over Covid-19 vaccine supply to European Union Member States. Despite the urgency of the...

Pharmaceutical Pricing Hostages

Ireland seems to be the stage of some of the most bizarre pharmaceutical company behaviour these days. This month, the pharmaceutical company CSL Behring...

Modifier la législation européenne pour mettre en œuvre la licence d’office en France

Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. » L’augmentation croissante du prix...

Humiragate: AbbVie’s desperate attempts to keep its monopoly

A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...

Commission report on competition enforcement in the pharmaceutical sector

Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...

Wrapping up 2024: Noteworthy events in medicines law and policy around the globe

Welcome to Medicines Law & Policy’s  end of the year blog, our highly biased annual overview of memorable medicines law and policy events. January At the...

Human Rights Watch: All governments should endorse the WHO C-TAP Solidarity Call to Action

As the race towards a Covid-19 vaccine continues – with 11 leading candidates in phase 3 clinical trials, 14 more in phase 2 and...

Covid-19 intellectual property pool gaining support

While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should...

Medicines Patent Pool signs first Covid-19 licence agreement with Merck Sharp & Dohme. Others...

The Medicines Patent Pool, a UN-backed organisation whose mission is to expand access to essential medicines around the world, today announced its first agreement...